Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
12/08/2025 14:31
Acurx Pharmaceuticals Inc ACXP.OQ reported a quarterly adjusted loss of $1.89 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-5.20. The mean expectation of three analysts for the quarter was for a loss of $2.27 per share. Wall Street expected results to range from $-2.60 to $-2.00 per share. Reported revenue was zero; analysts expected zero. Acurx Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.89. The company reported a quarterly loss of $2.25 million. Acurx Pharmaceuticals Inc shares had fallen by 56.1% this quarter and lost 72.5% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 38.2% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $130.00, about 96.6% above its last closing price of $4.48 This summary was machine generated from LSEG data August 12 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -2.27 | -1.89 | Beat |
| Mar. 31 2025 | -3.00 | -2.20 | Beat |
| Dec. 31 2024 | -3.60 | -3.20 | Beat |
| Sep. 30 2024 | -4.00 | -3.40 | Beat |
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln